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Aim. In postcardiac surgery patients, we assessed the performance of a system for intensive intravenous insulin therapy using
continuous glucose monitoring (CGM) and enhanced model predictive control (eMPC) algorithm. Methods. Glucose control in
eMPC-CGM group (𝑛 = 12) was compared with a control (C) group (𝑛 = 12) treated by intravenous insulin infusion adjusted
according to eMPC protocol with a variable sampling interval alone. In the eMPC-CGM group glucose measured with a REAL-
Time CGM system (Guardian RT) served as input for the eMPC adjusting insulin infusion every 15 minutes. The accuracy of
CGMwas evaluated hourly using reference arterial glucose and Clarke error-grid analysis (C-EGA). Target glucose range was 4.4–
6.1mmol/L. Results. Of the 277 paired CGM-reference glycemic values, 270 (97.5%) were in clinically acceptable zones of C-EGA
and only 7 (2.5%) were in unacceptable D zone. Glucose control in eMPC-CGM group was comparable to C group in all measured
values (average glycemia, percentage of time above, within, and below target range,). No episode of hypoglycemia (<2.9 mmol)
occurred in eMPC-CGM group compared to 2 in C group. Conclusion. Our data show that the combination of eMPC algorithm
with CGM is reliable and accurate enough to test this approach in a larger study population.
1. Introduction
Stress hyperglycemia (e.g., “diabetes of injury”) is a common
finding in critical care occurring in up to 90% of patients with
critical illness [1, 2]. It is associated with increased morbidity
andmortality and poorer prognosis of these patients [1–3]. In
2001, the landmark Leuven study performed in cardiosurgical
intensive care unit (ICU) demonstrated that intensive insulin
therapy (IIT) aimed at maintaining glycemia between 4.4
and 6.1mmol/L reduced mortality and decreased frequency
of severe organ complications [3]. Several other studies con-
firmed these findings especially in cardiac surgery patients
[4]. However, some of the more recent trials questioned
safety, reproducibility, and universality of beneficial effects of
tight glycemic control (TGC) in other subgroups of critically
ill patients [5–7], leading consequently to a shift towards a less
intensive approach to glucose lowering in ICU settings in the
last years.
Principally, the need to decrease pathologically elevated
glycemia in critically ill subjects has been generally accepted,
although the exact target range in various patient subgroups is
subject of ongoing discussion [1]. Numerous protocols for IIT
of variable effectiveness have been developed [1], with most-
recently introduced computer-based predictive algorithms
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showing significantly better performance with less adverse
effects compared to standard paper-based protocols [8, 9].
The main complication limiting the use of TGC procedures
is the occurrence of hypoglycemia, which was associated
with increased risk of death and prolonged ICU stay in
several studies [5–7]. As the response of ICU patients to
hypoglycemia is often blunted [1], frequent glucose monitor-
ing is an essential prerequisite of nearly all IIT algorithms.
However, frequent blood sampling increases dramatically the
workload of the nursing staff and the intermittent fashion, in
which glucose values are obtained, may not always capture
significant hypoglycemic events. Continuous glucose moni-
toring (CGM) could therefore be an ideal tool for catching
rapid glycemic excursions (both hypo- and hyperglycemia)
and providing the algorithmwith (nearly) real-time glycemic
data in order to improve its efficacy and safety.
To our knowledge only a minimum number of studies
including CGM as input for TGC in the ICU and utilizing
predominantly nonpredictive IIT protocols have been per-
formed so far [10–13]. To this end, we performed a single-
center randomized open-label trial using a combination
of the established computer-based eMPC (enhanced model
predictive control) algorithmwith a standard system for con-
tinuous glucose monitoring Guardian REAL-Time CGMS
(MiniMed Medtronic, Northridge, CA, USA). We evaluated
the efficacy and safety of the combined system and compared
it with the performance of the eMPC algorithm alone.
2. Research Design and Methods
2.1. Study Design and Subjects. The study was designed
as a single-center open-label randomized trial. 24 adult
patients (16 men and 6 women, aged 46 to 83 years, 5
patients with type 2 diabetes mellitus) undergoing major
elective cardiac surgery (aortocoronary bypass or valvular
plastic) were enrolled into the study. Twelve patients were
randomized for intensive insulin treatment with the eMPC
(enhancedmodel predictive control) protocol combinedwith
continuous glucose measurement (eMPC-CGM group) and
12 were randomized for insulin treatment according to eMPC
algorithm alone, which was routinely used at the Depart-
ment of Cardiovascular Surgery, General UniversityHospital,
Prague. Exclusion criteria were defined as follows: insulin
allergy and inability to sign informed consent. Characteristics
of both groups are shown in Table 1.
After patients’ admission to the ICU the glucose sensor
was inserted into the adipose tissue in the abdominal region
and continuous glucose monitoring was started after run-
in period of 1h 45min. The insulin infusion in both groups
of patients started 1 h 45 minutes (sensor run-in period in
eMPC-CGMgroup) after patients’ arrival at the ICU from the
operating theater and lasted for 24 hours. No routine protocol
was used for perioperative glucose control.
eMPC algorithm and continuous glucose measurement
were implemented by the ICU nursing staff with supervision
of an ICUphysician as required. Protocol trainingwas carried
out by the ICU physician and a departmental nurse, usually
individually, at bedside.
Table 1: Baseline characteristics of postcardiac surgery patients at
the time of admission at ICU. Data are mean ± SEM.
eMPC eMPC-CGM
Number of patients (𝑛) 12 12
Age (years) 67.5 ± 3.3 68.1 ± 2.2
Female (𝑛) 4 6
Ethnicity: Caucasian (%) 100 100
BMI (kg/m2) 27.8 ± 1.0 29.1 ± 0.8
Type of surgery (𝑛):
CABG 6 8
Valve replacement 4 3
CABG + valve replacement 2 1
History of diabetes (𝑛) 4 2
Previous insulin treatment (𝑛) 2 0
Arterial hypertension (𝑛) 11 11
Dislipidemia (𝑛) 2 6
2.2. Informed Consent. A written informed consent was
signed by all participants before being enrolled into the study.
The study was approved by the Human Ethical Review Com-
mittee, General University Hospital, Prague, Czech Republic,
and was performed in accordance with the guidelines pro-
posed in the Declaration of Helsinki.
2.3. Target Glucose Range. The target glucose range was set
to 4.4 to 6.1mmol/L, a level, which has been shown to
reduce mortality and morbidity in cardiosurgical critically ill
patients [3].
2.4. Patients’ Examination. Clinical parameters and patients’
clinical history data including age, sex, race, height, weight,
BMI, history of diabetes and other chronic diseases, and type
of surgery were collected prospectively.
2.5. Blood Glucose Monitoring, Insulin Treatment Regi-
mens, and Nutrition. Blood glucose (BG) was monitored
and insulin was administered according to each protocol
rules/suggestions. Undiluted arterial blood for measure-
ment of BG was drawn from an arterial line, inserted for
routine monitoring procedures. Whole blood glucose was
analyzed by a standard point-of-care testing device (ABL 700,
Radiometer Medical, Copenhagen, Denmark).
Insulin (Actrapid HM, Novo Nordisk, Baegsvard, Den-
mark) was given into a central venous line as a continuous
infusion in both groups. A standard concentration of 50
IU of insulin in 50mL of 0.9% NaCl was used. In all
patients, infusion of 10% glucose solution was initiated upon
admission to ICUwith a glucose dose of 2.5 g/kg of ideal body
weight (height in centimeters minus 100) per hour and lasted
for 18 hours, when normal oral food intake was started. In
ventilated patients, the glucose infusion lasted longer than the
monitored 24 hour.
Adverse events, medication, and nutrition were continu-
ously monitored and documented.
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2.6. Continuous Glucose Monitoring, eMPC Algorithm, and
Their Combination. A real-time continuous glucose mon-
itoring system, Guardian REAL-Time CGMS (MiniMed
Medtronic, Northridge, CA, USA), was used for continuous
glucose measurement. A subcutaneous glucose sensor was
inserted under the skin in the abdominal region immediately
after arriving in the ICU. The monitoring started after a
run-in period of 1 h 45min. Glucose was measured every 5
minutes and displayed on the monitoring unit. The system
was calibrated using arterial blood glucose concentrations
measured by a standard point-of-care testing device (ABL
700, Radiometer Medical A/S, Copenhagen, Denmark).
The enhanced model predictive (eMCP) algorithm used
in this studywas described in detail elsewhere [9, 14]. Glucose
concentration, insulin dosage, and carbohydrate intake were
the input variables for the eMPC and the output was the
insulin infusion rate. The eMPC was implemented on a
laptop computer. Control groupwas treated by this algorithm
alone, while the variable sampling interval for the next
blood glucose measurement calculated by the eMPC was
respected. Arterial glucose was used as input for the eMPC.
For a detailed description of the eMPC algorithm see the
Appendix. The main computer interface of eMPC is also
shown in Figure 3.
In the eMPC-CGM group data from CGM were entered
manually into the eMPC every 15 minutes, while the variable
sampling interval was not respected. Each hour glucose value
from continuous glucose monitor was compared to reference
arterial glucose using the Clarke error-grid analysis (C-EGA)
[15] and when clinically unacceptable (zone C, D, or E of C-
EGA) reference glycemia was used as input for the eMPC and
to recalibrate the Guardian REAL-Time. When no additional
calibration was needed, the sensor was calibrated every 12
hours as recommended by themanufacturer. In case of sensor
failure (i.e., inability to calibrate) the study was interrupted
and TGC was resumed using reference glycemia.
2.7. Outcome Measures. The performance of Guardian
REAL-Time CGMS was evaluated using Clarke Error-Grid
Analysis (C-EGA), a standard tool for assessing accuracy of
glucose meters [15]. The number of additional recalibrations
of each sensor and the number of sensor failures were
recorded.
Endpoints for effectiveness assessment of the TGC pro-
tocols were as follows: entire study average glycemia level;
time to the target range of 4.4–6.1mmol/L (80–110mg/dL);
average blood glucose level after reaching the target range;
time within, above and below the target range throughout the
whole study period and after reaching the target range; num-
ber of hypoglycemic episodes (≤2.9mmol/L). The percent-
ages of time in the specific ranges were calculated as number
of hours in the selected range in each patient/24∗ 100.
2.8. Statistical Analysis. Statistical analysis was performed
using SigmaStat software (Jandel Scientific, USA).The results
are expressed as mean ± standard error of the mean (SEM).
The TGC protocols were compared using Student’s t-test or
Mann-Whitney Rank Sum test as appropriate. Significance
level was set at 𝑃 = 0.05.
3. Results
Baseline characteristics of both study groups are listed in
Table 1. The groups did not differ with respect to age, race,
BMI, type of surgery, history of diabetes mellitus, and arterial
hypertension. Baseline blood glucose was significantly higher
in the eMPC-CGM group.
The performance of Guardian REAL-Time CGMS evalu-
ated byC-EGA is shown in Figure 1. Of the 277 paired glucose
values (values from the Guardian RT system and reference
arterial glucose measured at the same time) obtained during
the study, 270 (97.5%) were found in the acceptable A and B
ranges of C-EGA (66.4% inA zone and 31.1% in B zone). Only
7 values (2.5%) were in the D zone with none of them being
in the C and E zones.
Of the 12 sensors used in the study (1 sensor for each
patient), 6 needed no additional calibration except for the
2 obligatory ones (initially and after 12 hours). Of the
other 6 sensors, 4 needed 1 extra recalibration, while the
remaining 2 sensors had to be calibrated 3 ormore times. One
sensor failed after 21 hours, while the other 11 completed the
designed 24-hour testing time.
Performance of both TGC approaches using blood
glucose-based endpoints is summarized in Table 2, while
absolute glucose values throughout the whole testing period
for both groups are depicted in Figure 2. The eMPC-
CGM protocol showed similar glucose control compared to
eMPC group as assessed by average blood glucose (6.2 ±
0.1 versus 6.1 ± 0.6mmol/L, n.s.) and time spent in and
above the target range throughout the whole study (46.3±5.5
versus 46.2 ± 6.5 and 40.6 ± 5.9 versus 38.4 ± 5.1% of time,
resp., n.s.) and also after reaching the target range. Time
below the target range tended to be shorter in the eMPC-
CGM group (13.1 ± 2.6 versus 15.4 ± 2.4 and 18.8 ± 3.8
versus 22.2 ± 4.6% of time, resp., n.s.), but without any
statistical significance. Two episodes of severe hypoglycemia
defined as blood glucose equal or below 2.9mmol/L were
observed in the control group, while no such episode was
recorded in patients treated with eMPC-CGMprotocol. Both
hypoglycemic episodes were classified as “asymptomatic” and
were not related to established major risk factors of ICU
hypoglycemia such as nutritional interruption, asynchrony
of nutrition and insulin administration, delayed glucose
measurement, or drug administration. The combination of
eMPC and Guardian REAL-Time tended to be more efficient
in reaching the target levels of 4.4–6.1mmol/L (7.6±1.0 versus
8.8 ± 5.4 hours, n.s.).
4. Discussion
In the present study we tested the feasibility of a combination
of an established computer-based protocol for tight glucose
control (TGC) with a real-time continuous glucose moni-
toring system (CGM). This combination showed reasonable
accuracy and reliability and resulted in similar glucose
control as the computer-based algorithm alone.
Compared with diabetic patients, where the precision of
various CGM systems has been extensively tested, much less
data is available for individuals with critical illness. [16–19].
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Figure 1: Clarke Error-Grid Analysis of data from Guardian RT during the whole study period. Zone A (accurate), within 20% of reference
values, zone B (benign erroneous), outside of 20%, but not leading to inappropriate treatment, zones A and B, clinically acceptable accuracy.
Zone C (unnecessary correction), leading to overcorrection of acceptable glucose levels, zone D, potentially dangerous failure to detect hypo-
or hyperglycemia, zone E (erroneous treatment), erroneous treatment of hypo- or hyperglycemia (for hypoglycemia in case of hyperglycemia
and vice versa), zones C+D+E—clinically unacceptable.
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Figure 2: Glucose values in both groups throughout the study period. Values are means ± SD.
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Figure 3
Table 2: The study blood glucose control data. Data are expressed as mean ± SEM. The percentages of time in the specific ranges were
calculated as number of hours in the selected range in each patient/24∗ 100.
eMPC eMPC + Guardian 𝑃
Baseline blood glucose 8.1 ± 0.6 9.9 ± 0.4 <0.05
The entire study blood glucose control data
Average blood glucose (mmol/L) 6.1 ± 0.6 6.2 ± 0.1 n.s.
Time in target range (%) 46.2 ± 6.5 46.3 ± 5.5 n.s.
Time above target range (>6.1mmol/L; %) 38.4 ± 5.1 40.6 ± 5.9 n.s.
Time below target range (<4.4mmol/L; %) 15.4 ± 2.4 13.1 ± 2.6 n.s.
Severe hypoglycemia episodes (≤2.9mmol/L) 2 0
Blood glucose control data after reaching the target range (4.4–6.1mmol/L)
Average blood glucose (mmol/L) 5.2 ± 0.78 5.3 ± 0.1 n.s.
Time to target range (h) 8.8 ± 5.4 7.6 ± 1.0 n.s.
Time in target range (%) 62.8 ± 10.72 63.9 ± 5.4 n.s.
Time above target range (>6.1mmol/L; %) 15.0 ± 8.6 17.3 ± 6.2 n.s.
Time below target range (<4.4mmol/L; %) 22.2 ± 4.6 18.8 ± 3.8 n.s.
Severe hypoglycemia episodes (≤2.9mmol/L) 2 0
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Moreover, most of the studies that evaluated the performance
of subcutaneous sensor-based CGM systems in ICU set-
tings yielded conflicting results, with several trials reporting
unsatisfactory correlation of continuous and systemic glucose
[20, 21], insufficient accuracy of continuous systems [22],
or underestimated hypoglycemia [23], whereas in others
CGM systems provided clinically reliable measurements and
correlated tightly with reference glucose values [24–29].
The accuracy of Guardian REAL-Time CGMS in our study
with 97.5% values in the acceptable range of C-EGA was
comparable to most of the data collected in other ICU trials
and in routine diabetic patients. Nevertheless, it has to be
stressed that subjects included into our studywere specifically
admitted for elective cardiac surgery. Therefore we cannot
make general conclusionswith respect to sensor performance
in different, possibly more severely ill populations. Guardian
REAL-Time CGMS sensors showed high reliability with 10
sensors requiring 0 to 1 calibration in addition to the standard
2 calibrations in 24 hours specified by the manufacturer for
diabetic patients. Only 1 sensor failed to complete the whole
24-hour testing period. The sensors were well tolerated with
no major local complications (significant bleeding, infection,
irritation, pain). No serious technical or operational prob-
lems were recorded during the study.
The eMPC algorithm proved its effectiveness in main-
taining target glycemia in several clinical trials [9, 30–32].
In a study recently conducted in our surgical ICU the
performance of eMPC using intermittent glucose values
was compared to two other TGC algorithms—the Matias
protocol, which uses absolute glucose values, and the Bath
algorithm based on relative glucose change. The eMPC
protocol demonstrated the highest efficacy in achieving and
maintaining glucose in the target range without excessive risk
of severe hypoglycemic events [32]. In the present study the
performance of the eMPC algorithm corresponded largely to
results obtained in previous trials.
Only few studies have tried to combine CGM with TGM
algorithms. A system using retrospective CGMS in a real-
time manner coupled with a sliding scale algorithm in a
closed-loop fashion developed by Chee et al. did not show
significantly better performance compared tomanual control
[10]. In the so far largest trial evaluating real-timeCGM in the
ICU settings, including 124 mechanically ventilated patients
and using a routine Leuven-derived protocol governed either
by Guardian REAL-Time or intermittent arterial glycemia,
CGM did not improve the allover glycemic control (time
spent in target range, time to target range), although it
significantly reduced number of hypoglycemic events [12].
In this study the eMPC-CGM combination resulted
in similar glucose control compared to the use of eMPC
algorithm alone as assessed by no significant differences in
average glycemia and percentage of time in or above target
range. The combined system required less time to reach the
target levels and patients in the eMPC-CGM group tended
to spend less time under the target range compared to
the control group, but also without statistical significance.
However, considering higher baseline blood glucose in the
eMPC-CGM study arm, the inclusion of a CGM device
seems to at least partially improve the performance of the
eMPC algorithm. Moreover, no severe hypoglycemia (≤2.9)
was observed in the eMPC-CGM group compared to 2
episodes in the eMPC group. These findings are of major
importance in the light of recent large multicentric studies
aiming at tight glucose control, which were discontinued
due to excessive risk of hypoglycemia—the Glucontrol and
the VISEP study [5, 7]—and particularly the NICE-SUGAR
trial, where intensive insulin treatment targeted at normal
glycemic levels was associated with an increased risk of
hypoglycemia and overallmortality [6]. A largemeta-analysis
including all important TGC trials further confirmed a causal
relationship between hypoglycemia prevalence and increased
mortality. [33]. Therefore, our combination of eMPC and
CGM seems to offer promising opportunities to achieve TGC
goals in a safer manner, that is, without excessive risk of
hypoglycemic episodes.
We are aware of several limitations of our study. As this
was a study intendedmainly at testing the practical feasibility
of the proposed approach, the number of subjects in each
study armwas relatively low.The potential of continuous glu-
cosemonitoringmight not have been completely exploited, as
continuous values were inserted into the eMPC in 15-minute
intervals, even though they were updated every 5 minutes.
Furthermore, the low rate of hypoglycemic events could be
attributed to the relatively high constant rate of glucose infu-
sion administered throughout the study. A constant high rate
glucose infusion is expected to accelerate glucose turnover
and the overall system response [34]. It is still possible that the
overall outcome of the studywould differ under the condition
of a lower parenteral glucose administration and the results
thus cannot be generalized. Finally, despite the absence of
any severe hypoglycemic episode, the relatively long period of
time spent under the target range in the eMPC-CGM group
(in spite of being shorter than in the control group) might be
of some concern as well.
5. Conclusion
In conclusion, the results of our pilot feasibility trial indicate
that a combination of the computer-based enhanced model
predictive control algorithm with continuous glucose mon-
itoring by Guardian REAL-Time CGMS in cardiac surgery
patients is reliable, accurate, and efficient enough to test this
approach in larger populations.This treatment strategymight
represent a further step towards a fully automated closed-
loop system for insulin delivery in the critically ill, providing
a temporary solution until the so-far largely experimental
intravenous continuous glucose sensors are generally avail-
able.
Appendix
The eMPC Algorithm
The eMPC includes a model of the glucoregulatory sys-
tem, which adapts itself to the input-output relationship
observed during tight glucose control; that is, an incoming
glucose measurement is used by the model to update model
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parameters such as insulin sensitivity taking into account
previously given insulin and parenteral and enteral glucose.
Once individualized to a critically ill subject, the eMPC uses
the glucoregulatorymodel to determine the optimum insulin
infusion rate which is expected to achieve the target glucose
concentration. This is achieved by numerical optimization
using simulated experiments with the individualized glu-
coregulatory model. The output of this optimization is a
sequence of insulin infusion rates which are expected, based
on model predictions, to result in the target glucose concen-
tration over a period of 4 hours.The first insulin infusion rate
is displayed to the user and recommended for the delivery.
Thedetermination of the time-to-next glucose sample utilizes
prediction accuracy. Through an internal procedure, the
eMPC estimates how accurately it is able to predict glucose
concentration. The extent of accuracy will differ over time
as the unexplained variability in glucose concentration varies
due to, for example, temporal variations in insulin sensitivity.
The estimated prediction accuracy is used by the eMPC to
plot a prediction envelope. This is a funnel-like prediction
shape indicating a range of possible glucose concentrations
at each time point in the future. Once the prediction funnel
crosses a border indicating nonacceptable bounds, this might
be a level indicating a risk of hypoglycaemia or unacceptable
hyperglycaemia, the eMPC suggests a sample to be taken.
Glucose concentration, insulin dosage, and carbohydrate
intake are the input variables for the eMPC. The insulin
infusion rate and the time of the next glucose sample are
the outputs. The eMPC was implemented on a bedside PC
terminal.
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